- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
New radiopharmaceutical enters testing
Draxis Health of Mississauga, ON, has gotten the nod from Canadian officials to begin clinical trails of a radiopharmaceutical designed to image difficult-to-diagnose infections. The radiopharmaceutical promises to selectively distinguish infection from
Draxis Health of Mississauga, ON, has gotten the nod from Canadian officials to begin clinical trails of a radiopharmaceutical designed to image difficult-to-diagnose infections. The radiopharmaceutical promises to selectively distinguish infection from inflammation by binding directly with bacteria. It combines the widely used antibacterial agent ciprofloxacin with technetium-99m.Enrollment in the study is scheduled to begin in January. The Phase I study, to be conducted at Hôpital Hotel-Dieu, Centre Hospitalier de L'Université de Montréal, will involve 10 healthy subjects. Whole-body images will be taken periodically after injection of the drug to visualize its distribution throughout the body over time.
AI Mammography Platform Shows Promising Results for Detecting Subclinical Breast Cancer
October 3rd 2024Mean artificial intelligence (AI) scoring for breasts developing cancer was double that of contralateral breasts at initial biennial screening and was 16 times higher at the third biennial screening, according to a study involving over 116,000 women with no prior history of breast cancer.
FDA Clears Software for Enhancing CCTA Assessment of Atherosclerosis
October 1st 2024Through analysis of coronary computed tomography angiography (CCTA) images, the PlaqueIQ software provides quantification and classification of atherosclerosis, a common cause of myocardial infarction (MI) and ischemic stroke.
